GlassScriptPhysician profile
Danish Thameem
NPI 1821035106
$353,369.78
in general payments reported to CMS, 2019-2025
45 companies · $112K in 2025
The $112K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,841 · 2020: $4,287 · 2021: $13K · 2022: $30K · 2023: $48K · 2024: $144K · 2025: $112K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $247K · Travel and Lodging: $36K · Food and Beverage: $14K · Consulting Fee: $7,803 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $246,845.07 |
| Travel and Lodging | $35,688.88 |
| Food and Beverage | $13,550.03 |
| Consulting Fee | $7,803.00 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $188,746.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $143,636.88 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $8,903.16 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $4,233.08 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,707.32 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $574.92 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Mylan Specialty L.P. | $505.54 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $388.02 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $318.75 | 2019-2025 | Arikayce |
| Electromed, INC. | $314.38 | 2021-2025 | Smartvest |
| Pfizer INC. | $274.80 | 2020-2023 | |
| Viatris Specialty LLC | $254.39 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $249.12 | 2019-2024 | Xywav |
| Bayer Healthcare Pharmaceuticals INC. | $245.48 | 2019-2024 | |
| United Therapeutics Corporation | $240.44 | 2019-2025 | Tyvaso, Tyvaso |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $226.09 | 2019-2022 | |
| Amgen INC. | $206.34 | 2020-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $204.65 | 2020-2025 | Glassia, Cuvitru |
| Sunovion Pharmaceuticals INC. | $203.80 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $193.05 | 2020 | |
| Phadia US INC. | $186.68 | 2019-2023 | Immunocap |
| Verona Pharma, INC. | $181.49 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $128.37 | 2020-2023 | Airduo Digihaler |
| Axsome Therapeutics, INC. | $115.34 | 2023-2025 | Sunosi |
| Vapotherm INC | $107.75 | 2019 | |
| Genentech USA, INC. | $103.99 | 2019-2024 | Xolair |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Inspire Medical Systems, INC. | $82.07 | 2023-2025 | Inspire |
| Eisai INC. | $81.31 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $80.08 | 2019-2023 | |
| Advanced Respiratory, INC | $77.22 | 2019-2021 | |
| Lilly USA, LLC | $71.62 | 2025 | Zepbound |
| Pulmonx Corporation | $69.05 | 2019-2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Baxter Healthcare | $64.01 | 2021-2024 | Hillrom - Vest System Model 105 Home Care |
| E.R. Squibb & Sons, L.L.C. | $49.54 | 2021-2024 | Eliquis |
| Circassia INC. | $46.63 | 2019 | |
| Philips North America LLC | $37.07 | 2019-2024 | (Ak6) Vest Therapy |
| Mayne Pharma Commercial LLC | $27.56 | 2022 | |
| Medtronic, INC. | $23.39 | 2021 | |
| Novo Nordisk INC | $22.31 | 2021 | |
| Nabriva Therapeutics, Plc | $20.28 | 2020 | |
| Merck Sharp & Dohme LLC | $19.61 | 2025 | Winrevair |
| Kiniksa Pharmaceuticals International, Plc | $18.30 | 2024 | Arcalyst |
| Resmed Corp | $15.65 | 2024 | |
| Dexcom, INC. | $13.37 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danish Thameem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.